NO312578B1 - Farmasöytisk kombinasjonspreparat - Google Patents

Farmasöytisk kombinasjonspreparat Download PDF

Info

Publication number: NO312578B1
Authority: NO; Norway
Prior art keywords: cilazapril; endothelin; blood pressure; inhibitor; heart failure
Prior art date: 1993-07-15

Application number

NO19942650A

Other languages

English (en)

Norwegian (no)

Other versions

NO942650D0 (no

NO942650L (no

Inventor

Jean-Paul Clozel

Martine Clozel

Wolfgang Osterrieder

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-15

Filing date

1994-07-14

Publication date

2002-06-03

1994-07-14 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1994-07-14 Publication of NO942650D0 publication Critical patent/NO942650D0/no

1995-01-16 Publication of NO942650L publication Critical patent/NO942650L/no

2002-06-03 Publication of NO312578B1 publication Critical patent/NO312578B1/no

Links

238000002360 preparation method Methods 0.000 title claims description 9
206010019280 Heart failures Diseases 0.000 claims abstract description 12
239000002308 endothelin receptor antagonist Substances 0.000 claims abstract description 10
206010020772 Hypertension Diseases 0.000 claims abstract description 9
229940078123 Ras inhibitor Drugs 0.000 claims abstract description 9
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims description 18
229960005025 cilazapril Drugs 0.000 claims description 18
239000005541 ACE inhibitor Substances 0.000 claims description 6
239000013543 active substance Substances 0.000 claims description 6
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 6
GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 3
238000004806 packaging method and process Methods 0.000 claims 1
230000036454 renin-angiotensin system Effects 0.000 abstract description 6
239000003112 inhibitor Substances 0.000 abstract description 4
102000002045 Endothelin Human genes 0.000 description 15
108050009340 Endothelin Proteins 0.000 description 15
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 15
229940126062 Compound A Drugs 0.000 description 14
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 14
230000036772 blood pressure Effects 0.000 description 12
230000000694 effects Effects 0.000 description 11
241000700159 Rattus Species 0.000 description 10
239000003826 tablet Substances 0.000 description 9
238000002474 experimental method Methods 0.000 description 8
239000007903 gelatin capsule Substances 0.000 description 8
241000282693 Cercopithecidae Species 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000005557 antagonist Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 5
108090000783 Renin Proteins 0.000 description 4
230000004872 arterial blood pressure Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
229960004702 remikiren Drugs 0.000 description 4
ZHIQVOYGQFSRBZ-VQXQMPIVSA-N remikiren Chemical compound C([C@H](CS(=O)(=O)C(C)(C)C)C(=O)N[C@@H](CC=1[N]C=NC=1)C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)C1CC1)C1=CC=CC=C1 ZHIQVOYGQFSRBZ-VQXQMPIVSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
102000005862 Angiotensin II Human genes 0.000 description 3
101800000733 Angiotensin-2 Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
102100028255 Renin Human genes 0.000 description 3
206010047139 Vasoconstriction Diseases 0.000 description 3
229950006323 angiotensin ii Drugs 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
239000008298 dragée Substances 0.000 description 3
239000007941 film coated tablet Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000025033 vasoconstriction Effects 0.000 description 3
101800000734 Angiotensin-1 Proteins 0.000 description 2
102400000344 Angiotensin-1 Human genes 0.000 description 2
108010064733 Angiotensins Proteins 0.000 description 2
102000015427 Angiotensins Human genes 0.000 description 2
206010021036 Hyponatraemia Diseases 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
230000009471 action Effects 0.000 description 2
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000008512 biological response Effects 0.000 description 2
230000004531 blood pressure lowering effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000012636 effector Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
239000003925 fat Substances 0.000 description 2
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000011835 investigation Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000002461 renin inhibitor Substances 0.000 description 2
229940086526 renin-inhibitors Drugs 0.000 description 2
238000011699 spontaneously hypertensive rat Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000001993 wax Substances 0.000 description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102000004881 Angiotensinogen Human genes 0.000 description 1
108090001067 Angiotensinogen Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000282695 Saimiri Species 0.000 description 1
241000282696 Saimiri sciureus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
238000002513 implantation Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
-1 invert sugar Substances 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
229940063711 lasix Drugs 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)

NO19942650A 1993-07-15 1994-07-14 Farmasöytisk kombinasjonspreparat NO312578B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH213193		1993-07-15

Publications (3)

Publication Number	Publication Date
NO942650D0 NO942650D0 (no)	1994-07-14
NO942650L NO942650L (no)	1995-01-16
NO312578B1 true NO312578B1 (no)	2002-06-03

Family

ID=4226611

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19942650A NO312578B1 (no)	1993-07-15	1994-07-14	Farmasöytisk kombinasjonspreparat

Country Status (25)

Country	Link
US (1)	US5696116A (fr)
EP (1)	EP0634175B1 (fr)
JP (1)	JP2746537B2 (fr)
KR (1)	KR100370181B1 (fr)
CN (1)	CN1105573C (fr)
AT (1)	ATE198551T1 (fr)
AU (1)	AU683262B2 (fr)
BR (1)	BR9402815A (fr)
CA (1)	CA2128142C (fr)
CZ (1)	CZ285413B6 (fr)
DE (1)	DE59409631D1 (fr)
DK (1)	DK0634175T3 (fr)
ES (1)	ES2154277T3 (fr)
GR (1)	GR3035702T3 (fr)
HU (1)	HU221202B1 (fr)
IL (1)	IL110272A (fr)
NO (1)	NO312578B1 (fr)
NZ (1)	NZ260969A (fr)
PL (1)	PL176445B1 (fr)
PT (1)	PT634175E (fr)
RU (1)	RU2146522C1 (fr)
SA (1)	SA94150155B1 (fr)
TW (1)	TW287949B (fr)
UA (1)	UA27870C2 (fr)
ZA (1)	ZA944980B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5514696A (en) *	1992-05-06	1996-05-07	Bristol-Myers Squibb Co.	Phenyl sulfonamide endothelin antagonists
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5760038A (en) *	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) *	1995-02-06	1998-07-14	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) *	1995-07-24	1998-12-08	Bristol-Myers Squibb Co.	Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja)	1995-10-11	1997-05-13	Bristol Myers Squibb Co	置換ビフェニルスルホンアミドエンドセリン拮抗剤
JP2001523218A (ja)	1996-02-20	2001-11-20	ブリストル―マイヤーズ・スクイブ・カンパニー	ビフェニルイソキサゾール・スルホンアミドの製造法
US5856507A (en) *	1997-01-21	1999-01-05	Bristol-Myers Squibb Co.	Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) *	1996-04-09	1999-08-17	Bristol-Myers Squibb Co.	Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
AU6187898A (en) *	1997-01-30	1998-08-25	Bristol-Myers Squibb Company	Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) *	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU750755B2 (en) *	1997-09-26	2002-07-25	Abbvie Deutschland Gmbh & Co Kg	Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation
US6638937B2 (en)	1998-07-06	2003-10-28	Bristol-Myers Squibb Co.	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CN1234357C (zh) *	1998-07-10	2006-01-04	诺瓦提斯公司	缬沙坦和钙通道阻断剂的抗超敏组合
US6136971A (en) *	1998-07-17	2000-10-24	Roche Colorado Corporation	Preparation of sulfonamides
CN101011390A (zh) *	1999-01-26	2007-08-08	诺瓦提斯公司	血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
HUP0201320A2 (en)	1999-03-19	2002-08-28	Bristol Myers Squibb Co	Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
DE60131032T2 (de) *	2000-08-25	2008-08-14	Research Corp. Technologies, Inc., Tucson	Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
PT1517682E (pt) *	2002-06-28	2007-02-28	Speedel Pharma Ag	Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
CN1838957A (zh) *	2003-08-22	2006-09-27	舍林股份公司	抑制趋化因子的哌嗪衍生物及其治疗心肌炎的用途
CN101312962A (zh) *	2005-12-06	2008-11-26	参天制药株式会社	角膜结膜病变的治疗剂
EP2091539A1 (fr) *	2006-12-12	2009-08-26	Gilead Colorado, Inc.	Utilisation de l'ambrisentan associé avec un inhibiteur de rénine dans les troubles de l'hypertension
US8080549B2 (en) *	2007-01-12	2011-12-20	Concert Pharmaceuticals, Inc.	Endothelin receptor antagonists
US8071596B2 (en)	2007-01-12	2011-12-06	Concert Pharmaceuticals, Inc.	Endothelin receptor antagonists
KR20150079373A (ko)	2013-12-30	2015-07-08	한미약품 주식회사	에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
WO2018002673A1 (fr)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
MA49664A (fr)	2017-02-27	2020-06-03	Idorsia Pharmaceuticals Ltd	Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS559058A (en) *	1978-07-06	1980-01-22	Dainippon Pharmaceut Co Ltd	1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
IL58849A (en) *	1978-12-11	1983-03-31	Merck & Co Inc	Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4470972A (en) *	1981-04-28	1984-09-11	Schering Corporation	7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
US4337201A (en) *	1980-12-04	1982-06-29	E. R. Squibb & Sons, Inc.	Phosphinylalkanoyl substituted prolines
AT377496B (de) *	1981-06-19	1985-03-25	Voith Gmbh J M	Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
US4410520A (en) *	1981-11-09	1983-10-18	Ciba-Geigy Corporation	3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) *	1982-05-12	1985-05-22	Hoffmann La Roche	Diaza-bicyclic compounds
DE3542794A1 (de) *	1985-12-04	1987-06-11	Bayer Ag	Antihypertensives kombinationspraeparat
DE58905990D1 (de) *	1988-03-24	1993-12-02	Hoffmann La Roche	Antihypertensives Kombinationspräparat.
JPH06505474A (ja) *	1991-01-31	1994-06-23	アボツト・ラボラトリーズ	エンドセリン転換酵素阻害剤
MX9200299A (es) *	1991-02-07	1992-12-01	Roussel Uclaf	Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
ATE156120T1 (de) *	1991-02-07	1997-08-15	Roussel Uclaf	Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
RU2086544C1 (ru) *	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW216770B (fr) *	1991-07-23	1993-12-01	Hoffmann La Roche
US5378715A (en) *	1992-02-24	1995-01-03	Bristol-Myers Squibb Co.	Sulfonamide endothelin antagonists
US5420123A (en) *	1992-12-21	1995-05-30	Bristol-Myers Squibb Company	Dibenzodiazepine endothelin antagonists

1994
- 1994-06-29 PT PT94110064T patent/PT634175E/pt unknown
- 1994-06-29 DK DK94110064T patent/DK0634175T3/da active
- 1994-06-29 DE DE59409631T patent/DE59409631D1/de not_active Expired - Lifetime
- 1994-06-29 EP EP94110064A patent/EP0634175B1/fr not_active Expired - Lifetime
- 1994-06-29 ES ES94110064T patent/ES2154277T3/es not_active Expired - Lifetime
- 1994-06-29 AT AT94110064T patent/ATE198551T1/de active
- 1994-07-08 AU AU67357/94A patent/AU683262B2/en not_active Expired
- 1994-07-08 ZA ZA944980A patent/ZA944980B/xx unknown
- 1994-07-08 NZ NZ260969A patent/NZ260969A/en not_active IP Right Cessation
- 1994-07-11 HU HU9402064A patent/HU221202B1/hu unknown
- 1994-07-11 IL IL11027294A patent/IL110272A/en not_active IP Right Cessation
- 1994-07-12 US US08/273,663 patent/US5696116A/en not_active Expired - Lifetime
- 1994-07-12 JP JP6160010A patent/JP2746537B2/ja not_active Expired - Lifetime
- 1994-07-12 CZ CZ941677A patent/CZ285413B6/cs not_active IP Right Cessation
- 1994-07-14 KR KR1019940016899A patent/KR100370181B1/ko not_active IP Right Cessation
- 1994-07-14 CN CN94108595A patent/CN1105573C/zh not_active Expired - Lifetime
- 1994-07-14 NO NO19942650A patent/NO312578B1/no not_active IP Right Cessation
- 1994-07-14 BR BR9402815A patent/BR9402815A/pt not_active Application Discontinuation
- 1994-07-14 UA UA94075635A patent/UA27870C2/uk unknown
- 1994-07-14 PL PL94304292A patent/PL176445B1/pl unknown
- 1994-07-14 TW TW083106428A patent/TW287949B/zh not_active IP Right Cessation
- 1994-07-14 RU RU94026283A patent/RU2146522C1/ru active
- 1994-07-15 CA CA002128142A patent/CA2128142C/fr not_active Expired - Lifetime
- 1994-08-29 SA SA94150155A patent/SA94150155B1/ar unknown
2001
- 2001-04-05 GR GR20010400550T patent/GR3035702T3/el unknown

Also Published As

Publication number	Publication date
PL304292A1 (en)	1995-01-23
DE59409631D1 (de)	2001-02-15
DK0634175T3 (da)	2001-04-30
RU94026283A (ru)	1996-05-20
ATE198551T1 (de)	2001-01-15
UA27870C2 (uk)	2000-10-16
NO942650D0 (no)	1994-07-14
CZ285413B6 (cs)	1999-08-11
CA2128142C (fr)	2007-03-06
HU221202B1 (en)	2002-08-28
NZ260969A (en)	1996-01-26
CZ167794A3 (en)	1995-01-18
AU683262B2 (en)	1997-11-06
RU2146522C1 (ru)	2000-03-20
JPH0753408A (ja)	1995-02-28
KR960013371A (ko)	1996-05-22
CN1105573C (zh)	2003-04-16
AU6735794A (en)	1995-01-27
PL176445B1 (pl)	1999-05-31
IL110272A0 (en)	1994-10-21
BR9402815A (pt)	1995-04-04
ES2154277T3 (es)	2001-04-01
EP0634175A1 (fr)	1995-01-18
CN1107364A (zh)	1995-08-30
CA2128142A1 (fr)	1995-01-16
KR100370181B1 (ko)	2003-04-26
NO942650L (no)	1995-01-16
US5696116A (en)	1997-12-09
HU9402064D0 (en)	1994-09-28
EP0634175B1 (fr)	2001-01-10
GR3035702T3 (en)	2001-07-31
JP2746537B2 (ja)	1998-05-06
SA94150155B1 (ar)	2005-11-15
IL110272A (en)	1998-07-15
PT634175E (pt)	2001-06-29
HUT67331A (en)	1995-03-28
TW287949B (fr)	1996-10-11
ZA944980B (en)	1995-02-06

Legal Events

Date	Code	Title	Description
2014-07-21	MK1K	Patent expired

Publication	Publication Date	Title
NO312578B1 (no)	2002-06-03	Farmasöytisk kombinasjonspreparat
EP1437131B1 (fr)	2012-04-25	Utilisation de ramipril pour la prévention du diabète chez un patient sans insuffisance cardiaque congestive préexisitante
RU2401107C2 (ru)	2010-10-10	Фармацевтическая композиция, содержащая амлодипин и лозартан
US20080027032A1 (en)	2008-01-31	Combinations comprising cox-2 inhibitors and aspirin
JP2010515682A (ja)	2010-05-13	喘息などの５−リポキシゲナーゼ活性上昇および／またはロイコトリエン活性上昇に関連する状態における使用のためのｒ−ジロートン
EP0708644A1 (fr)	1996-05-01	TRAITEMENT DE L'INFECTION PAR $i(CRYPTOCOCCUS NEOFORMANS)
EP3411021A1 (fr)	2018-12-12	Nouvelle utilisation d'une combinaison de sacubitril et de valsartan
CA2013801A1 (fr)	1990-10-05	Compositions synergiques contenant de la cetanserine
WO1996031234A1 (fr)	1996-10-10	Compositions de combinaison contenant benazeprile ou benazeprilat et valsartane
JP2009510056A (ja)	2009-03-12	血圧を低下させる方法
RU2213577C2 (ru)	2003-10-10	Фармацевтический препарат
EP2837380B1 (fr)	2019-04-03	Préparation constituée de chlorhydrate de lercanidipine et de losartan potassique et son procédé de préparation
EP1441723B1 (fr)	2007-05-02	Utilisation de l'irbesartan pour la prevention ou le traitement de l'hypertension pulmonaire
WO2004075892A2 (fr)	2004-09-10	Traitement combine de l'hypertension au moyen de lercanidipine et d'un bloqueur des recepteurs de l'angiotensine ii
JP2020520948A5 (fr)	2021-07-26
CN110755429A (zh)	2020-02-07	一种复方降压药组合物、其制剂及其用途
NZ243577A (en)	1994-09-27	Synergistic anti-hypertensive composition containing tetrahydronaphthalene and pyridodiazepine derivatives
CN109069438A (zh)	2018-12-21	包含β阻滞剂、转化酶抑制剂和抗高血压药或NSAID的药物组合物
US20180311241A1 (en)	2018-11-01	Pharmaceutical synergistic combination
van Hamersvelt	1994	Natriuretic effects of dihydropyridine calcium entry blockers
KR20090090748A (ko)	2009-08-26	조합 성분을 함유한 혈관질환 예방치료제
NO334451B1 (no)	2014-03-03	Medikament for anvendelse til forhindring og/eller behandling av hypertensjon eller arteriosklerose og anvendelse av bestanddelene til fremstilling av et medikament for slik anvendelse.
MXPA00002654A (en)	2001-05-17	Endothelin antagonist and beta receptor blocking agent as combined preparations
WO2006010005A1 (fr)	2006-01-26	Abaissement de l'acide urique pour prevenir l'insuffisance renale aigue ou en accelerer la guerison